GlassScriptPhysician profile
Taj Richardson
NPI 1679343693
$6,217.54
in general payments reported to CMS, 2019-2025
24 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $3,491 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,118 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,117.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $937.08 | 2024-2025 | Tremfya |
| Abbvie INC. | $693.58 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $626.72 | 2024-2025 | Zoryve |
| Ucb, INC. | $585.96 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $443.46 | 2025 | |
| Novartis Pharmaceuticals Corporation | $364.96 | 2024-2025 | |
| Incyte Corporation | $346.76 | 2024-2025 | Opzelura, Opzelura |
| Pfizer INC. | $346.15 | 2024-2025 | |
| Lilly USA, LLC | $289.87 | 2024-2025 | Taltz, Ebglyss |
| Dermavant Sciences, INC. | $245.34 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $243.39 | 2024-2025 | |
| Galderma Laboratories, L.P. | $234.85 | 2024-2025 | Nemluvio |
| Organon LLC | $166.24 | 2025 | Vtama, Nexplanon |
| Regeneron Healthcare Solutions, INC. | $135.16 | 2025 | Libtayo, Dupixent |
| Paratek Pharmaceuticals, INC. | $121.13 | 2024 | Nuzyra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $109.00 | 2024 | Ycanth |
| Botanix Sb INC | $108.11 | 2025 | Sofdra |
| Amgen INC. | $75.87 | 2025 | Otezla |
| Leo Pharma INC. | $48.52 | 2025 | Spevigo, Anzupgo |
| Iovance Biotherapeutics, INC. | $32.24 | 2025 | Amtagvi |
| Lnhc, INC | $16.79 | 2025 | Zelsuvmi |
| Medimetriks Pharmaceuticals, INC. | $16.42 | 2025 | |
| Almirall LLC | $15.70 | 2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.24 | 2025 | Siliq, Cabtreo, Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taj Richardson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.